Roche to lead Israel stem cell consortium

The consortium is based on research by Prof. Joseph Itskovitz-Eldor of the Technion and Prof. Nissim Benvenisty of the Hebrew University.

Sources inform ''Globes'' that Roche Holding AG (SWX: ROG) is leading the establishment of a stem cell consortium based on intellectual property rights of Israeli universities. The consortium is based on research by Prof. Joseph Itskovitz-Eldor of the Technion Israel Institute of Technology and Prof. Nissim Benvenisty of the Hebrew University of Jerusalem. The consortium may add other operations at Tel Aviv University.

Roche and the Pontifax Fund will finance the consortium with several million dollars over the next few years. The two companies are partners, together with the Office of the Chief Scientist, in seed investments in Van Leer Ventures Jerusalem Ltd. portfolio companies. Roche also has a cooperation agreement with Yissum Technology Transfer Company of the Hebrew University of Jerusalem.

Although Israel is considered a world leader in stem cell research at universities and in commercial development, top stem cell researchers have not been involved in commercial ventures, with the exception of Hadasit Bio Holdings Ltd. (TASE:HDST) portfolio company CellCure Neurosciences Ltd., whose CSO, Prof. Benjamin Reubinoff is affiliated with Hadassah Medical Organization.

Itskovitz-Eldor and Benvenisty are world-class researchers in stem cells. They co-founded Van Leer Ventures portfolio company SCT - Stem Cell Technologies Ltd, which will apparently be the foundation for the consortium. SCT CEO Dr. Naomi Zak has degrees from Harvard and the Weizmann Institute of Science, and worked at the Hebrew University Hadassah University Hospital.

According to the Israel Venture Capital Association, SCT is engaged in the development of protocols to encourage the differentiation of stem cells into insulin excreting pancreas cells to treat diabetes. The company is also developing universal stem cells to treat liver failure by solving the problem of organ rejection.

Published by Globes [online], Israel business news - www.globes-online.com - on April 3, 2011

© Copyright of Globes Publisher Itonut (1983) Ltd. 2011

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Yaron Daniely Replacing Ritalin

Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.

Twitter Facebook Linkedin RSS Newsletters